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NPM1 gene mutation evaluated on a population basis is a valuable and realistic tool to reflect the pathophysiological relevance of cancer. In a
comparison of the NPM1 cDNA of human bladder cancer with its consensus sequence, we have found that a higher NPM1 sequence identity in a
population is consistent with poor tumor differentiation, advanced tumor stage, and likelihood of recurrence. These data imply that “probability”
of NPM1 mutation is an indicator of status of malignancy.
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Patient characteristics
No. %
Patients 43
Patient age (years)
Median 69
Range 35–90
Sex
Male 33 76.7
Female 10 23.3
T stage
pT1 29 67.4
pT2 5 11.6
pT3 8 18.6
pT4 1 2.3
Histologic grade
1 15 34.8Genetic variations in the human genome range from a single
nucleotide to megabases in size. While copy number variations
(CNVs) are widely seen in human cancers [1–5], single-
nucleotide polymorphisms (SNPs) may also play a role in
individual disease susceptibility [6]. Unlike the association of
CNVs with phenotype change, accumulation of nucleotide
changes in a gene in a population has not been well delineated.
Nucleophosmin (NPM; also known as B23, NO38, or
numatrin) is a multifunctional nucleolar phosphoprotein. NPM
has crucial roles in proliferation and homeostasis, such as ribo-
some biogenesis, centrosome duplication, cell cycle progress-
ion, and cell differentiation [7,8].
NPM is important in apoptosis and modulation of the ARF–
p53 tumor suppressor pathway [9]. With the intriguing bio-
logical function as an oncogene or a tumor suppressor, the gene
dosage, expression level, and genetic mutation of NPM1 have
been examined extensively [10].
In hematological malignancy, NPM1 translocations and the
resulting fusion proteins are often found. Patients with anaplastic
large cell lymphoma (ALCL) with NPM1/ALK t(2;5)(p23;q35)⁎ Corresponding author. Fax: +886 3 2118615.
E-mail address: byung@mail.cgu.edu.tw (B. Yat-Ming Yung).
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doi:10.1016/j.ygeno.2007.07.006translocation show excellent response to induction therapy and
are prone to better prognosis [11]. NPM1 exon 12 and cyto-
plasmic NPM mutant (NPMc+) in acute myelogenous leukemia2 18 41.9
3 10 23.3
Primary tumor 26 60.5
Recurrent tumor 17 39.5
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prognosis [12,13]. The genetics underlying the pathogenesis of
solid tumor, however, is poorly defined.
Over 90% of bladder cancers are transitional cell
carcinomas that have recurrence rates as high as 50–70%.
About 20% of recurrences progress to invasive cancer.
Metastatic bladder cancer is incurable and associated with
poor prognosis. Dyrskjot et al. have reported the molecular
signature of superficial bladder cancer with a propensity for
invasion [14]. The majority of these genes are involved in the
regulation of apoptosis, cell differentiation, and cell cycle
progression. We previously have shown that NPM mRNA
overexpression is associated with advanced tumor stages and
grades [15]. This prompts us to investigate the possible NPM1
genetic correlation with its clinical relevance. Since an event
of cancerous transformation is the final result of multiple
deregulations, a single genetic change may not be enough to
reflect to phenotype. It thus becomes conceivable and
important for us to evaluate genetic changes in NPM1 on a
population basis.Fig. 1. NPM1 population alignment. (A) NPM1 complexity in different clinicopatho
stage (T2–4), histological grade (G1, G2, G3), and primary (P) or recurrent (R) are as
start and end of cloned sequences; q and r, start and end of alignment to consensus N
pathological stage T1 and the bottom those of advanced stages (T2–T4). At the top
alignment in all specimens. α, arbitrary sample names; β, clinical/pathological informResults
With the approval of the Institutional Review Board for the
Protection of Human Subjects, 43 patients with bladder trans-
itional cell carcinoma diagnosed from 2002 to 2004 at Chang
Gung Memorial Hospital were recruited. Patients' ages ranged
from 35 to 90 years (median 69). Thirty-three (76.7%) patients
were male and 10 (23.3%) were female. Twenty-six (60.5%)
patients had primary and 17 (39.5%) had recurrent bladder
cancers. The pathological grading was 15 (34.8%) grade 1, 18
(41.9%) grade 2, and 8 (23.3%) grade 3 tumor. Twenty-nine
(67.4%) patients were pT1, 5 (11.6%) were pT2, 8 (18.6%)
were pT3, and 1 (2.3%) was pT4 stage (Table 1).
Tumors with similar pathological or clinical setting were
segregated for alignment to the consensus RefSeq cDNA
sequence of NPM1. With the algorithm of ClustalW applied in
the alignment analysis of vector NTI, the gene identity was
quantified. Fig. 1 shows the complexity of NPM1 in each
population. The shaggy appearance at the end of each bar
denotes the variation in the population alignment (Fig. 1A).logical settings. Bladder tumors of pathological superficial stage (T1), invasive
sorted for alignment. Sample number in each group is shown in Table 1. p and s,
PM1 cDNA. (B) NPM1 alignment at the C_terminus. The top shows tumors of
of each group is the consensus NPM1 sequence. Yellow color denotes identical
ation; γ, group alignment.
Fig. 1 (continued).
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NPM1 at the C-terminus (Fig. 1B). The identity of NPM1 with
the consensus in the pT1 population was 66.4%, whereas it was
88.7% in the population with invasive tumor (pT2–4). The
population gene identity in the group of pathological grade 1
was 70.5% and that in grades 2 and 3 was 87 and 89.5%,
respectively. The overall gene identity in primary tumor in this
cohort was 66.8%, while it was 88.3% in the population with
recurrent tumors (Fig. 2). Furthermore, in shorter sequence
comparison (restricted to 500 nucleotides), the sequence could
be highly identical to the consensus sequence (up to 99.8%).
The comparison can also be made to encompass the full cloning
sequences (extended comparison). The trend of higher NPM1
sequence identity appearing in tumors of high malignancy was
well preserved (Fig. 2). Bladder cancer with advanced tumor
stage, higher tumor grade, and higher status of recurrence shows
higher sequence identity to the consensus NPM1 cDNA. In thiscontext, NPM1 in bladder cancer acts more like a proto-
oncogene. The integrity of NPM1 shows increased probability
of completion of tumor behavior. Accumulation of genetic
variation results in defective malignancy potential and this can
be seen in either tumor staging or grading pathologically and
status of recurrence clinically. The concept of evaluating tumor
behavior on a population basis in relevance to the sequence
identity of a crucial cancer gene such as NPM1 will give us a
novel view in tumor genetics.
Discussion
Cancer is, in essence, a genetic disease [16]. Recent advances
in biotechnology such as microarrays enable researchers to
perform high-throughput comparisons of multiple genes
between different biological settings or conditions. Thousands
of genes with minor differences may be responsible for each
Fig. 2. NPM1 identity at different sequence lengths. Using NPM1 cDNA as the
alignment profile, higher NPM1 sequence identity in a population is consistent
with poor tumor differentiation, advanced tumor stage, and likelihood of
recurrence. This trend is seen in comparison to NPM1 cDNA and well preserved
at either restricted length (500 nucleotides) or extended comparison.
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divergent comparisons. Herein, we propose the convergent
comparison of a gene in a population by its identity to the
consensus sequence in different pathological and clinical
settings. We suspect that a gene that might work with our
hypothesis would be a pivotal gene involved in major cellular
activity. NPM1 is a transcription target of the proto-oncogene
Myc [17]. NPM regulates the stability and transcriptional
activity of p53 [9]. p53 has been linked to about half of human
cancers and its mutation has prognostic implications in bladder
cancers [18]. As a member of the nucleoplasmin family, NPM
acts as a molecular chaperone that shuttles rapidly between
nucleus and cytoplasm.With the diversity of its binding to many
partners, it is involved in much more complex biological activity
than expected.
One may expect that a tumor is the result of a genetic defect
that causes cell cycle deregulation and escape from the
surveillance of a tumor suppressor gene such as p53. One
may also be interested in finding possible clues to identify
subgroups in all cancer patients that will be more susceptible to
treatment outcome and better prognosis. Falini et al. reported
that mutation in the carboxy-terminus of NPM1 causes
encoding of abnormal proteins that are crucial for the nuclear
export signal motif and nucleolar localization [19]. These
mutants cause cytoplasmic localization of NPM. NPMc+
represents a subgroup of patients who have normal karyotypeand better prognosis. In fact, NPM exists in normal cells. Under
proliferating or tumorigenesis conditions, NPM will over-
express in response to the proliferative process or oncogenic
stress. Mutation in a pivotal gene and functional protein in
cancer cells could be associated with better treatment response
and prognosis.
It is well known that the strongest predictors in a clinical
scenario are tumor stage and grade. In this study, using a finite
alignment algorithm, the NPM1 identity in a population
correlates well with bladder tumor stage, grade, and recurrence
status. Our data imply that the probability of NPM1 mutation is
an indicator of clinical relevance in bladder cancer. Most
importantly, NPM1 genetic changes evaluated on a population
basis prove to be valuable and realistic in reflecting the
pathological and clinical settings of cancer. NPM1 is illustrated
to be a crucial gene in cancer genetics.
Materials and methods
Total RNA was extracted using the Trizol method (Invitrogen). Fresh
mRNAs were reverse transcribed to cDNA using M-MLV (Invitrogen). Both
forward and reverse primers spanning the NPM1 gene were analyzed to confirm
the fidelity of sequence. The forward primer was 5′-GCAGCGTTCTTT-
TATCTCCG-3′, about 37 bp upstream of the transcription start site. The reverse
primer was 5′-TAAAACCAAGCAAAGGGTGG-3′, about 180 bp downstream
of the transcription stop site. Primers were designed to encompass the full length
of NPM1 and for the fidelity of full-length sequencing of the gene. The
consensus sequence used was from NCBI (NM_002520) with the NPM1
sequence of 885 nucleotides. Sequences analysis for alignment, using NPM1 as
the profile, was performed using Vector NTI Suite 8 (InforMax).
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